FDA Approves New Alzheimer's Drug, Leqembi. Can It Escape Aduhelm's Fate?

January 07, 2023

Leqembi's starting price is almost half of what Aduhelm's was and the FDA-approved label narrows use to people with early disease. But Medicare coverage restrictions may still apply and there is concern about a side effect called ARIA (amyloid related imaging abnormalities).

Well-Administered Coumadin No Worse for Mental Function Than Pradaxa, Study Finds

December 14, 2022

Pradaxa (dabigatran) and Coumadin (warfarin) came out even in this randomized study. The Brazilian researchers who conducted the study said one explanation for the result is that use of Coumadin was exceptionally well managed because the patients were enrolled a study.

Variation by Age of EoE Symptoms May Contribute to Delayed Diagnosis for Some Patients

December 06, 2022

Patients with eosinophilic esophagitis experience a range of symptoms that can vary by age, which may contribute to younger patients experiencing a delay in diagnosis, according to a poster presented at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting.